Real Time Material Information

This information is provided by 3176 Medigen Biotech Corp. (TPEx Listed Company)

Item	1	Announcement Date	2021/05/11	Announcement Time	18:24:23
Spokesperson	Arlene Chiang	Spokesperson Position	Assistant Vice President, Operations Department	Contact Information	[02]2653- 5200#890
Subject	The Company's 2021 Q1 consolidated financial reports has been approved by the resolution of the Board of Directors				
Pursuant To Article	4	Subparagraph	31	Date of occurrence of event	2021/05/11
Details	1. Date of submission of financial reports to the board of directors or date of the board of directors' resolution: 2021/05/11 2. Date of approval of financial reports by the audit committee: NA 3. The start and end dates of the reporting period of the financial reports (XXX/XX/XX-XXX/XXX): 2021/01/01~2021/03/31 4. Cumulative operating revenue from January 1 to the end of the reporting period (thousand NTD): 185,654 5. Cumulative operating gross profit (gross loss) from January 1 to the end of the reporting period (thousand NTD): 88,756 6. Cumulative operating income (loss) from January 1 to the end of the reporting period (thousand NTD): (268,582) 7. Cumulative net profit (net loss) before tax from January 1 to the end of the reporting period (thousand NTD): (147,415) 8. Cumulative net profit (net loss) from January 1 to the end of the reporting period (thousand NTD): (158,788) 9. Cumulative net profit (loss) attributable to owners of the parent from January 1 to the end of the reporting period (thousand NTD): (64,100) 10. Cumulative basic earnings (loss) per share from January 1 to the end of the reporting period (NTD): (0.46) 11. Total assets at the end of the reporting period (thousand NTD): 6,217,834 12. Total liabilities at the end of the reporting period (thousand NTD): 1,677,926 13. Equity attributable to owners of the parent at the end of the reporting period (thousand NTD): 1,891,038 14. Any other matters that need to be specified: None.				

The above information is declared by the company in accordance with the regulations of the market it belongs to at the time, and released to the public through this system. The company shall hold sole responsibility if any false information is declared.